Who are bupivacaine with hydromorphone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lidocaine and sufentanil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bupivacaine-with-hydromorphone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

bupivacaine with hydromorphone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bupivacaine with hydromorphone (bupivacaine with hydromorphone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic and opioid analgesic combination. Area: Pain management.

phase 3 Local anesthetic and opioid analgesic combination Pain management Small molecule Live · refreshed every 30 min

Target snapshot

bupivacaine with hydromorphone (bupivacaine with hydromorphone) — University of Virginia. Bupivacaine with hydromorphone is a combination of a local anesthetic and an opioid analgesic that works by blocking nerve signals in the body and providing pain relief.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bupivacaine with hydromorphone TARGET	bupivacaine with hydromorphone	University of Virginia	phase 3	Local anesthetic and opioid analgesic combination
lidocaine and sufentanil	lidocaine and sufentanil	RenJi Hospital	marketed	Local anesthetic and opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic and opioid analgesic combination class)

RenJi Hospital · 1 drug in this class
University of Virginia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bupivacaine with hydromorphone — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-with-hydromorphone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab